Abstract

Despite recent advances in therapy, multiple myeloma (MM) remains
incurable, showing the need for novel therapies.

Melflufen is a lipophilic peptide-conjugated alkylator that rapidly
delivers a highly cytotoxic payload into myeloma cells through peptidase
activity.

Melflufen is currently under evaluation in phase III study for the
treatment multiple myeloma.

The poster describes the development of
Melflufen from early pre-clinical discovery to the currently on-going clinical
trials.